Acadia Pharmaceuticals (NASDAQ: ACAD)
Acadia Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Acadia Pharmaceuticals Company Info
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
News & Analysis
Investing in Biotech ETFs
Here are the five best biotech ETFs to invest in right now.
Why Acadia Pharmaceuticals Stock Is Rising Today
An analyst upgrade is sparking a rally in the drugmaker's shares today.
2 Growth Stocks I'd Buy on the Dip
These two growth stocks could be worthwhile buy-and-holds.
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
A top hedge fund has been steadily buying these two growth stocks in 2023.
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
This biotech stock has been on fire in 2023.
Why These 2 Biotech Stocks Made Big Moves Late Thursday
Markets kept powering higher on the day.
3 Nasdaq Stocks on Watch This Week
These three Nasdaq stocks are poised to make big moves in the coming week.
1 Top Biotech Stock to Buy in March
This biotech could land a major regulatory approval this month.
Valuation
Earnings Transcripts
Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript
ACAD earnings call for the period ending November 8, 2021.
Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript
ACAD earnings call for the period ending June 30, 2021.
Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript
ACAD earnings call for the period ending March 31, 2020.
Acadia Pharmaceuticals (ACAD) Q4 2019 Earnings Call Transcript
ACAD earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.